Vitamina D y Esclerosis Múltiple: Evidencia científica

White, 2008, Vitamin D signaling, infectious diseases and regulation of innate immunity, Infec Immun, 76, 3837, 10.1128/IAI.00353-08 Hernandez, 2000, Epidemiología de la esclerosis múltiple. Controversias y realidades, Rev Neurol, 30, 959 Casanova i Estruch B, Coret Ferrer F, Landete L, Burgal M. Afectación axonal en la esclerosis múltiple conceptos actuales. 1.er congreso virtual de neuroepidemiología. Noviembre 1998. [consultado 20 Feb 2012]. Disponible en: http://neurologia.rediris.es/congreso-1/conferencias/emultiple-4.html Mouzaki, 2004, Immunotherapy for multiple sclerosis: Basic insights for new clinical strategies, Curr Neurovasc Res, 1, 325, 10.2174/1567202043362180 Alemany-Rodríguez, 2005, Enfermedades autoinmunes y esclerosis múltiple, Rev Neurol, 40, 594 Lublin, 2005, History of modern multiple sclerosis therapy, J Neurol, 252, iii3 Weinshenker, 1989, The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability, Brain, 112, 133, 10.1093/brain/112.1.133 Ebers, 2005, Prognostic factors for multiple sclerosis: The importance of natural history studies, J Neurol, 252, iii15 Fazekas, 1988, Criteria for an increase specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis, Neurology, 38, 1822, 10.1212/WNL.38.12.1822 Filippi, 1995, Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: A follow-up study, Neurology, 45, 255, 10.1212/WNL.45.2.255 McAlpine, 1965 Poser, 1983, New diagnostic criteria for multiple sclerosis: Guidelines for research protocols, Ann Neurol, 13, 227, 10.1002/ana.410130302 Polman, 2005, Diagnostics criteria for multiple sclerosis: 2005 revisions to the «MacDonald criteria», Ann Neurol, 58, 840, 10.1002/ana.20703 Gilbert, 1983, Unsuspected multiple sclerosis, Arch Neurol, 40, 533, 10.1001/archneur.1983.04050080033003 Kremenchutzky M. Historia natural de la esclerosis múltiple: una revisión. 1.er congreso virtual de neuroepidemiología. Noviembre 1998. [consultado 20 Feb 2012]. Disponible en: http://neurologia.rediris.es/congreso-1/conferencias/emultiple-3.html Weinshenker, 1991, The natural history of multiple sclerosis: A geographically based study. 3. Multivariate analysis of predictive factors and models of outcome, Brain, 114, 1045, 10.1093/brain/114.2.1045 Sadovnick, 1993, Epidemiology of multiple sclerosis: A critical overview, Can J Neurol Sci, 20, 17, 10.1017/S0317167100047351 Dickinson, 2009, Past enviromental sun exposure and risk of multiple sclerosis: A rol for the CDX-2 vitamin D receptor, Mult Scler, 15, 563, 10.1177/1352458509102459 Kurtzke, 1975, A reassessment of the distribution of multiple sclerosis, Acta Neurol Scand, 51, 137, 10.1111/j.1600-0404.1975.tb01365.x Smolders, 2008, Vitamin D as an immune modulator in multiple sclerosis, a review, J Neuroimmunol, 194, 7, 10.1016/j.jneuroim.2007.11.014 Corona, 1996, Multiple sclerosis in Mexico: Hospital cases at the National Institute of Neurology and Neurosurgery, Mexico City, Neurología, 11, 170 Velázquez-Quintana, 2003, Multiple sclerosis in Mexico: A multicentre study, Rev Neurol, 36, 1019 Van Amerongen, 2004, Multiple sclerosis and vitamin D: An update, Eur J Clin Nutr, 58, 1095, 10.1038/sj.ejcn.1601952 Dusso, 2005, Vitamin D. Am J Physiol Renal Physiol, 289, 8, 10.1152/ajprenal.00336.2004 Schwarz, 2005, Multiple sclerosis and nutrition, Multip Scler, 11, 24, 10.1191/1352458505ms1119oa Villegas Silva E. Departamento de Química Universidad Agraria la Molina. Lima. Perú. Agenda Química Virtual. Semana 51. Diciembre 2011. Goldberg, 1974, Multiple sclerosis: Vitamin D and calcium as environmental determinants of prevalence, Intern J Environmental Studies, 6, 121, 10.1080/00207237408709641 Coo, 2004, A systematic review of several potential non-genetic risk factors for multiple sclerosis, Neuroepidemiol, 23, 1, 10.1159/000073969 Farinotti, 2007, Dietary interventions for multiple sclerosis (Review), Cochrane Database Syst Rev, 24, CD004192 Eyles, 2003, VitaminD3 and brain development, Neuroscience, 118, 641, 10.1016/S0306-4522(03)00040-X Eyles, 2005, Distribution of the vitamin D receptor and alphahydroxylase in human brain, J Chem Neuroanat, 29, 21, 10.1016/j.jchemneu.2004.08.006 Garcion, 2002, New clues about vitamin D functions in the nervous system, Trends Endocrinol Metab, 13, 100, 10.1016/S1043-2760(01)00547-1 Stumpf, 1982, Brain target sites for 1,25-dihydroxyvitamin D3, Science, 215, 1403, 10.1126/science.6977846 Stumpf, 1988, 1,25(OH)2 vitamin D3 sites of action in spinal cord and sensory ganglion, Anat Embryol, 177, 307, 10.1007/BF00315837 Pérez-Fernandez, 1997, Vitamin D receptor gene expression in human pituitary gland, Life Sci, 60, 35, 10.1016/S0024-3205(96)00586-3 Zehnder, 2001, Extrarenal expression of 25-hydroxyvitamin d(3)-1 alphahydroxylase, J Clin Endocrinol Metab, 86, 888, 10.1210/jc.86.2.888 Johnson, 1996, 1,25-dihydroxyvitamin D(3) receptors in developing dorsal root ganglia of fetal rats, Brain Res Dev Brain Res, 92, 120, 10.1016/0165-3806(95)00204-9 Langub, 2001, Evidence of functional vitamin D receptors in rat hippocampus, Neuroscience, 104, 49, 10.1016/S0306-4522(01)00049-5 Luine, 1987, Vitamin D: Is the brain a target, Steroids, 49, 133, 10.1016/0039-128X(87)90082-1 Musiol, 1992, Vitamin D nuclear binding to neurons of the septal, substriatal and amygdaloid area in the Siberian hamster (Phodopus sungorus) brain, Neuroscience, 48, 841, 10.1016/0306-4522(92)90272-4 Baas, 2000, Rat oligodendrocytes express the vitamin D(3) receptor and respond to 1,25-dihydroxyvitamin D(3), Glia, 31, 59, 10.1002/(SICI)1098-1136(200007)31:1<59::AID-GLIA60>3.0.CO;2-Y Cornet, 1998, 1,25-dihydroxyvitamin D3 regulates the expression of VDR and NGF gene in Schwann cells in vitro, J Neurosci Res, 53, 742, 10.1002/(SICI)1097-4547(19980915)53:6<742::AID-JNR11>3.0.CO;2-# Walbert, 2001, Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the limbic system of the rat, Horm Metab Res, 33, 525, 10.1055/s-2001-17210 Prufer, 1999, Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord, J Chem Neuroanat, 16, 135, 10.1016/S0891-0618(99)00002-2 Glaser, 1999, Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat olfactory system, Cell Mol Neurobiol, 19, 613, 10.1023/A:1006932418220 Zou, 2008, Progressive hearing loss in mice with a mutated vitamin D receptor gene, Audiol Neurootol, 13, 219, 10.1159/000115431 Rupprecht, 1999, Neuroactive steroids: Mechanisms of action and neuropsychopharmacological perspectives, Trends Neurosci, 22, 410, 10.1016/S0166-2236(99)01399-5 Jia, 1999, Immunochemical studies on the putative plasmalemmal receptor for 1,25-dihydroxyvitamin D3 II. Chick kidney and brain, Steroids, 64, 541, 10.1016/S0039-128X(99)00030-6 Melcangi, 2001, Steroids in the nervous system: A Pandora's box, Trends Neurosci, 24, 311, 10.1016/S0166-2236(00)01820-8 McGrath, 2001, Vitamin D: The neglected neurosteroid, Trends Neurosci, 24, 570, 10.1016/S0166-2236(00)01949-4 Zakon, 1998, The effects of steroid hormones on electrical activity of excitable cells, Trends Neurosci, 21, 202, 10.1016/S0166-2236(97)01209-5 Brewer, 2001, Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons, J Neurosci, 21, 98, 10.1523/JNEUROSCI.21-01-00098.2001 Brewer, 2006, Chronic 1alpha, 25-(OH)2 vitamin D3 treatment reduces Ca2+)-mediated hippocampal biomarkers of aging, Cell Calcium, 40, 277, 10.1016/j.ceca.2006.04.001 Kimura, 1998, Role of glutamate receptors and voltage-dependent calcium and sodium channels in the extracellular glutamate/aspartate accumulation and subsequent neuronal injury induced by oxygen/glucose deprivation in cultured hippocampal neurons, J Pharmacol Exp Ther, 285, 178 Garcion, 1999, 1,25-dihydroxyvitamin D3 regulates the synthesis of gamma-glutamyl transpeptidase and glutathione levels in rat primary astrocytes, J Neurochem, 73, 859, 10.1046/j.1471-4159.1999.0730859.x Ibi, 2001, Protective effect of 1 alpha,25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture, Neuropharmacology, 40, 761, 10.1016/S0028-3908(01)00009-0 Taniura, 2006, Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons, J Neurosci Res, 83, 1179, 10.1002/jnr.20824 Dawson, 1996, Nitric oxide neurotoxicity, J Chem Neuroanat, 10, 179, 10.1016/0891-0618(96)00148-2 Shinpo, 2000, Effect of 1,25-dihydroxyvitamin D(3) on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by L-buthionine sulfoximine and 1-methyl-4-phenylpyridine, J Neurosci Res, 62, 374, 10.1002/1097-4547(20001101)62:3<374::AID-JNR7>3.0.CO;2-7 Cass, 2006, Calcitriol protects against the dopamineand serotonindepleting effects of neurotoxic doses of methamphetamine, Ann N Y Acad Sci, 1074, 261, 10.1196/annals.1369.023 Buell, 2008, Vitamin D and neurocognitive dysfunction: Preventing decline, Mol Aspects Med, 29, 415, 10.1016/j.mam.2008.05.001 Cantorna, 1998, 1,25-dihydroxyvitamin D3 is a positive regulator for the two antiencephalitogenic cytokines TGF beta 1 and IL4, J Immunol, 160, 5314, 10.4049/jimmunol.160.11.5314 Cantorna, 1996, 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis, Proc Natl Acad Sci U S A, 93, 7861, 10.1073/pnas.93.15.7861 Woo, 2006, Regulation of cortical interneurons by neurotrophins: From development to cognitive disorders, Neuroscientist, 12, 43, 10.1177/1073858405284360 Kiraly, 2006, Vitamin D as a neuroactive substance: Review, ScientificWorldJournal, 6, 125, 10.1100/tsw.2006.25 Simpson, 2011, Latitude is significantly associated with the prevalence of multiple sclerosis: A meta-analysis, J Neurol Neurosurg Psychiatry, 82, 1132, 10.1136/jnnp.2011.240432 Staples, 2010, Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: Longitudinal analysis, BMJ, 340, c1640 Kampman, 2008, Vitamin D: A candidate for the enviromental effect in multiple sclerosis, Neuroepidemiology, 30, 140, 10.1159/000122330 Mahon, 2003, Cytokine profile in patients with multiple sclerosis following vitamin D supplementation, J Neuroimmunol, 134, 128, 10.1016/S0165-5728(02)00396-X Dickinson, 2009, Past environmental sun exposure and risk of multiple sclerosis: A role for the Cdx-2 vitamin D receptor variant in this interaction, Mult Scler, 15, 563, 10.1177/1352458509102459 Kragt, 2009, Hogher levels of 25 hidroxyvitamin D are associated with lower incidence of multiple sclerosis only in women, Mult Scler, 15, 9, 10.1177/1352458508095920 Orton, 2011, Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians, J Neurol Sci, 305, 116, 10.1016/j.jns.2011.02.032 Kampman, 2010, The role of vitamin D in multiple sclerosis, J Photochem Photobiol B, 101, 137, 10.1016/j.jphotobiol.2010.04.003 Ascherio, 2010, Vitamin D and multiple sclerosis, Lancet Neurol, 9, 599, 10.1016/S1474-4422(10)70086-7 Anzgene, 2009, Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20, Nat Genet, 41, 824, 10.1038/ng.396 Simpson, 2010, Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis, Ann Neurol, 68, 193 Pozuelo-Moyano, 2012, A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis, Neuroepidemiology, 40, 147, 10.1159/000345122